AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

INTRODUCTION: Isocitrate dehydrogenase (IDH) mutations are disease-defining mutations in IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas. In more than 80% of these tumors, point mutations in IDH type 1 (IDH1) lead to expression of the tumor-specific protein IDH1R132H....

Descripción completa

Detalles Bibliográficos
Autores principales: Bunse, Lukas, Rupp, Anne-Kathleen, Poschke, Isabel, Bunse, Theresa, Lindner, Katharina, Wick, Antje, Blobner, Jens, Misch, Martin, Tabatabai, Ghazaleh, Glas, Martin, Schnell, Oliver, Gempt, Jens, Denk, Monika, Reifenberger, Guido, Bendszus, Martin, Wuchter, Patrick, Steinbach, Joachim P, Wick, Wolfgang, Platten, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125855/
https://www.ncbi.nlm.nih.gov/pubmed/35599302
http://dx.doi.org/10.1186/s42466-022-00184-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125855/
https://www.ncbi.nlm.nih.gov/pubmed/35599302
http://dx.doi.org/10.1186/s42466-022-00184-x

Ejemplares similares